Technical Analysis for ZURA - Zura Bio Limited
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -2.66% | |
Wide Bands | Range Expansion | -2.66% | |
Gapped Up | Strength | -2.66% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -0.54% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.54% | |
NR7 | Range Contraction | -0.54% | |
Inside Day | Range Contraction | -0.54% | |
Wide Bands | Range Expansion | -0.54% | |
Upper Bollinger Band Walk | Strength | -0.18% |
Alert | Time |
---|---|
Down 5% | 2 days ago |
Fell Below Previous Day's Low | 2 days ago |
Possible NR7 | 2 days ago |
Possible Inside Day | 2 days ago |
Down 3% | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Zura is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immunology Diabetes Monoclonal Antibody Antibody
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immunology Diabetes Monoclonal Antibody Antibody
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.9999 |
52 Week Low | 2.0 |
Average Volume | 375,046 |
200-Day Moving Average | 4.68 |
50-Day Moving Average | 3.82 |
20-Day Moving Average | 5.03 |
10-Day Moving Average | 5.53 |
Average True Range | 0.48 |
RSI (14) | 63.64 |
ADX | 47.83 |
+DI | 30.59 |
-DI | 11.68 |
Chandelier Exit (Long, 3 ATRs) | 4.92 |
Chandelier Exit (Short, 3 ATRs) | 4.79 |
Upper Bollinger Bands | 6.20 |
Lower Bollinger Band | 3.86 |
Percent B (%b) | 0.69 |
BandWidth | 46.48 |
MACD Line | 0.54 |
MACD Signal Line | 0.54 |
MACD Histogram | 0.0009 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.21 | ||||
Resistance 3 (R3) | 6.24 | 6.03 | 6.09 | ||
Resistance 2 (R2) | 6.03 | 5.85 | 6.02 | 6.05 | |
Resistance 1 (R1) | 5.76 | 5.73 | 5.66 | 5.73 | 6.01 |
Pivot Point | 5.55 | 5.55 | 5.50 | 5.54 | 5.55 |
Support 1 (S1) | 5.28 | 5.37 | 5.18 | 5.25 | 4.97 |
Support 2 (S2) | 5.07 | 5.25 | 5.06 | 4.93 | |
Support 3 (S3) | 4.80 | 5.07 | 4.89 | ||
Support 4 (S4) | 4.77 |